Neurosense Therapeutics is trading at $3.82, down 6.14%, with biotech-sector weakness the clearest context; no direct company-specific catalyst was established. - The XBI was down 2.50%; rising oil prices and Treasury yields weighed on broader equities. - A market report said the 10-year Treasury yield reached 5.34%, its highest level since 2002. No new company-specific announcement explaining the October 7 decline was identified; the Nasdaq listing-compliance update was announced October 2.